What Is 10-deacetylbaccatine III

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 11, 2026

Quick Answer: 10-Deacetylbaccatin III (10-DAB III) is a natural diterpenoid compound isolated from the Pacific and European yew trees (Taxus species) with the chemical formula C29H36O10. It serves as a critical precursor in the semi-synthetic manufacturing of paclitaxel (Taxol) and docetaxel (Taxotere), two major anti-cancer drugs used in chemotherapy since the 1990s.

Key Facts

Isolated from dried needles and branches of Taxus baccata (European yew tree) since the 1980s
Chemical formula C29H36O10 with CAS number 32981-86-5
Semi-synthetic conversion developed by Holton et al. and Potier's group revolutionized paclitaxel production
Converted to paclitaxel through acetylation at carbon 10 and esterification at carbon 13
Exhibits antileishmanial activity and biological properties beyond pharmaceutical manufacturing

Overview

10-Deacetylbaccatin III, commonly abbreviated as 10-DAB III, is a naturally occurring diterpenoid compound with profound significance in modern pharmaceutical manufacturing. This organic molecule, with the chemical formula C29H36O10, is extracted from the needles and small branches of the European yew tree (Taxus baccata) and other Taxus species found in Pacific regions. The compound represents a critical intermediate in the biosynthetic pathway of taxane alkaloids.

The discovery and isolation of 10-DAB III revolutionized the production of life-saving cancer medications. Rather than relying solely on harvesting limited natural sources, pharmaceutical chemists developed semi-synthetic routes to convert this abundant precursor into paclitaxel (Taxol) and docetaxel (Taxotere). This breakthrough addressed supply chain limitations and made these powerful anti-cancer drugs accessible to millions of patients worldwide since the 1990s.

How It Works

10-Deacetylbaccatin III functions as a naturally occurring scaffold that serves as the foundation for semi-synthetic drug manufacturing. The compound undergoes specific chemical transformations to produce clinically important taxanes:

Acetylation Reaction: A hydroxyl functional group at carbon 10 of the molecule is acetylated to form baccatin III, which is catalyzed by the enzyme 10-deacetylbaccatin III-10-O-acetyltransferase (DBAT) in biological systems or through chemical methods in laboratory settings.
Side Chain Esterification: An esterification reaction occurs at carbon 13, incorporating N-benzoyl-β-phenylisoserine in the specific 2R, 3S configuration to complete the transformation into paclitaxel.
Enzymatic Biotransformation: Whole-cell biotransformation approaches use living organisms to convert 10-DAB III into downstream intermediates, offering cost-effective and environmentally sustainable production methods for pharmaceutical manufacturers.
Multi-Step Synthesis: Chemical synthetic routes involve multiple sequential reactions that transform the natural scaffold into active pharmaceutical ingredients with controlled stereochemistry and purity levels exceeding 95% by HPLC analysis.
Docetaxel Production: Similar semi-synthetic pathways convert 10-DAB III into docetaxel (Taxotere) through different side-chain esterifications, demonstrating the compound's versatility as a precursor platform for multiple cancer medications.

Key Comparisons

Characteristic	10-Deacetylbaccatin III	Paclitaxel (Taxol)	Docetaxel (Taxotere)
Source	Extracted from Taxus baccata needles	Semi-synthetic from 10-DAB III	Semi-synthetic from 10-DAB III
Chemical Formula	C29H36O10	C47H51NO14	C43H53NO14
Availability	Limited natural supply, now cultivated	FDA-approved since 1992	FDA-approved since 1996
Primary Use	Drug precursor and intermediate	Breast and ovarian cancer treatment	Breast cancer and prostate cancer treatment
Biological Activity	Antileishmanial properties	Mitotic inhibitor, tubulin stabilizer	Mitotic inhibitor, tubulin stabilizer

Why It Matters

10-Deacetylbaccatin III represents a cornerstone innovation in sustainable pharmaceutical manufacturing. By utilizing this naturally abundant precursor, manufacturers reduced dependence on harvesting endangered yew trees, addressing both environmental and supply chain concerns that plagued anti-cancer drug production in the 1980s.

Cancer Treatment Access: Semi-synthetic production enabled paclitaxel to be manufactured at scale, making one of the most effective breast, ovarian, and lung cancer medications affordable and accessible to patients globally rather than limited by natural supply constraints.
Environmental Sustainability: The shift from natural harvesting to semi-synthetic manufacturing from 10-DAB III precursors eliminated the need to fell entire yew forests, protecting these slow-growing tree species that required decades to mature.
Cost Reduction: Semi-synthetic routes utilizing 10-DAB III reduced manufacturing costs by an estimated 50-70% compared to total chemical synthesis or natural extraction, improving patient access to life-saving therapies in developing nations.
Pharmaceutical Innovation: Success with 10-DAB III established the semi-synthetic template approach as a standard strategy for converting natural product scaffolds into clinically relevant medications, influencing modern drug discovery paradigms.
Research Applications: Beyond cancer treatment, 10-DAB III continues to serve as a research chemical (CAS#32981-86-5) in laboratories studying taxane chemistry, biosynthetic pathways, and structure-activity relationships for developing next-generation taxane variants.

The story of 10-deacetylbaccatin III exemplifies how scientific innovation bridges natural products chemistry with sustainable pharmaceutical manufacturing. By transforming a limited natural resource into an abundant synthetic intermediate, researchers created a scalable platform for producing taxane-based anti-cancer drugs that have saved millions of lives since FDA approval in the 1990s. Today, 10-DAB III remains essential to global cancer treatment infrastructure.